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HYPERTENSION
Hydrochlorothiazide Is Superior to Isradipine for Reduction of Left
Ventricular Mass: Results of a Multicenter Trial
VASILIOS PAPADEMETRIOU, MD, FACC, JOHN S. GOTTDIENER, MD, FACC,*
PUNEET NARAYAN, MD,* WILLIAM G. CUSHMAN, MD,† PRINCE K. ZACHARIAH, MD, FACC,‡
PATRICIA S. GOTTDIENER, MS,* GARY A. CHASE, PHD,* FOR THE ISRADIPINE STUDY GROUP§
Washington, D.C. and Jacksonville, Florida
Objectives. We sought to determine the efficacy of isradipine in
reducing left ventricular (LV) mass and wall thickness in hyper-
tensive patients.
Background. LV hypertrophy on the echocardiogram is a strong
predictor of cardiovascular events. Reduction of LV mass may be
a desirable goal of drug therapy for hypertension. However,
although thiazide diuretic drugs have been advocated as first-line
therapy for hypertension, their efficacy in reducing LV mass has
been questioned.
Methods. Patients with mild to moderate diastolic hypertension
and LV mass in excess of 1 SD of normal values were randomized
to isradipine (n 5 89) or hydrochlorothiazide therapy (n 5 45).
Evaluations were obtained at baseline, after 3 and 6 months of
treatment and 2 weeks after treatment was stopped.
Results. At 6 months, LV mass decreased by 43 6 45 g (mean 6
SD) with hydrochlorothiazide (p < 0.001) but only by 11 6 48 g
with isradipine (p 5 NS; between-group comparison, p < 0.001).
Two weeks after drug therapy was stopped, LV mass remained
24 6 41 g lower than that at baseline in the hydrochlorothiazide
group (p 5 0.003) but only 7 6 50 g lower in the isradipine group
(p 5 NS). Septal and posterior wall thicknesses were significantly
and equally reduced with both isradipine and hydrochlorothia-
zide. Greater LV mass reduction with hydrochlorothiazide was
related to a 2.8 6 3.3-mm reduction of LV cavity size with
hydrochlorothiazide but no reduction with isradipine. At 6 months
of treatment, diastolic blood pressure (BP) by design was equally
reduced in both treatment groups. At 3 months, systolic BP was
reduced by 17 6 15 mm Hg with isradipine and by 26 6 15 and
25 6 17 mm Hg at 3 and 6 months, respectively, with hydrochlo-
rothiazide (p 5 0.003, between-group comparison). However, on
stepwise multivariable regression analysis, treatment selection
(partial r2 5 0.082, p 5 0.001), change in average 24-h systolic BP
(partial r2 5 0.032, p 5 0.029) and change in average sitting
systolic BP (partial r2 5 0.017, p 5 0.096) were predictive of LV
mass reduction.
Conclusions. Despite an equivalent reduction of diastolic BP, 6
months of therapy with hydrochlorothiazide is associated with a
substantial reduction of LV mass, greater than that with isradip-
ine. The superior efficacy of hydrochlorothiazide for LV mass
reduction is associated with a greater reduction of systolic BP as
well as drug selection itself. These data may have important
therapeutic implications.
(J Am Coll Cardiol 1997;30:1802–8)
©1997 by the American College of Cardiology
Increased left ventricular (LV) mass, even below partition
values used to define the presence of hypertrophy, is an
important predictor of cardiovascular morbidity and mortality
(1–3). Moreover, some studies (4,5) suggest that regression of
LV hypertrophy and mass may produce benefits over and
above those derived from control of hypertension alone.
Although not all antihypertensive drugs are effective for
reduction of LV mass (6), previous studies have indicated that
dihydropyridine calcium antagonists (7,8) including isradipine
(9), can be effective. Some reports are conflicting (10); how-
ever, several (11–14) have indicated that thiazide diuretic
drugs are minimally effective in reducing LV mass. Moreover,
even with reduction of LV mass, it has been suggested (13) that
diuretic drugs may act through volume depletion without
decreasing LV wall thickness.
However, many studies of LV mass reduction have been
criticized for methodologic limitations, including short dura-
tion (often 6 to 12 weeks), inadequate control subjects, small
numbers of patients and uncertain blinding (11,15). Moreover,
most previous studies have failed to adjust for covariates other
than drug selection, such as body weight and systolic blood
pressure (BP), which are known to influence LV mass (16,17).
The present study was designed to test the hypothesis that
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in patients in whom isradipine (a dihydropyridine calcium
channel blocking agent) produces adequate reduction of dia-
stolic BP, the drug might also be effective for the reduction of
LV mass and wall thickness, without adversely affecting LV
function. The study was a randomized, double-blind, diastolic
titration, parallel-group study of 134 patients with mild to
moderate hypertension conducted in 18 centers across the
United States. The trial was 6 months in duration and recruited
patients with established hypertension and relatively high LV
mass. Hence, use of a placebo with absence of BP control for
that period was not ethically feasible. However, because hy-
drochlorothiazide is known to be effective for control of BP but
believed to be ineffective for reduction of LV mass, it was
selected as an alternative to placebo for comparison with
isradipine. To enhance the study’s power to detect changes
with isradipine, a 2:1 randomization scheme was utilized.
Methods
Patient eligibility. Male and female patients, 21 years or
older, with uncomplicated systemic hypertension were eligible
for the study. Female patients had to be postmenopausal or
surgically sterilized. To qualify for the study, patients had to
demonstrate a sitting diastolic BP between 90 and 114 mm Hg
(inclusive) at previous clinical evaluations and at the last two
visits of the placebo run-in period and a mean awake 24-h
ambulatory BP monitoring diastolic reading .90 mm Hg at the
baseline visit.
It was assumed that reduction of LV mass would be more
readily demonstrated in patients with a relatively high LV mass
at baseline. Hence, a partition value for LV mass of 119 g/m2
(body surface area) for men and 98 g/m2 for women was
arbitrarily selected to ensure relatively a high LV mass but not
to unduly limit recruitment by restricting patients to those who
exceeded the partition value for LV hypertrophy. The partition
value for LV mass, normalized for body surface area, was
determined as the average plus 1 SD of LV mass previously
established by Devereux et al. (18) for normal subjects. The
echocardiogram for this determination was acquired at the end
of the screening period. If the patient fulfilled all criteria for
entry into the study, a second echocardiogram was acquired at
the end of the placebo run-in period. This second pretreatment
study served as the “baseline” echocardiogram to minimize
regression to the mean.
Study exclusions. Patients were excluded from the study if
one or more of the following criteria were present: malignant
or accelerated hypertension; secondary forms of hypertension;
severe cardiac disease such as angina pectoris; history of
myocardial infarction; percutaneous transluminal coronary an-
gioplasty; bypass surgery or stroke in the last 6 months;
symptomatic congestive heart failure; systolic BP .199 mm Hg
or diastolic BP .114 mm Hg; any medical condition that would
compromise participation; or an echocardiogram of insuffi-
cient technical quality.
Study design. After a screening phase, suitable patients
underwent a placebo run-in period during which they under-
went clinical and laboratory assessment, serial BP measure-
ment and 24-h ambulatory BP monitoring. Patients who met
BP criteria for the study on ambulatory BP monitoring under-
went screening two-dimensional targeted M-mode echocardi-
ography to determine eligibility.
Interventions. Patients were randomized at a ratio of 2:1 to
receive isradipine (n 5 159) or hydrochlorothiazide (n 5 82).
Compliance was monitored by pill count at each visit. The
study drug dose was titrated every 2 weeks to obtain BP
control, which was defined as a sitting diastolic BP ,90 mm Hg
and at least 5 mm Hg below the baseline value for patients with
a baseline value of 90 to 94 mm Hg; or ,95 mm Hg and at least
10 mm Hg below the baseline value for patients with a baseline
value of 95 to 114 mm Hg. Isradipine was titrated as needed
from 2.5 mg twice a day to 5, 7.5 or 10 mg twice daily and
hydrochlorothiazide from 25 mg once a day to 50 mg daily. At
the end of the titration phase, patients continued to take the
lowest dose of isradipine or hydrochlorothiazide that con-
trolled their BP. If BP was not controlled at the highest
allowed dose, the patient was censored from the study.
After completing the titration phase, patients were seen
every 4 weeks during a 6-month maintenance phase for
measurement of BP and heart rate and assessment of compli-
ance and side effects. At 3 and 6 months of the maintenance
period, all patients underwent echocardiography and 24-h
ambulatory BP monitoring.
Posttreatment procedures. After the 6-month mainte-
nance period, all patients entered a 2-week placebo washout
period, at the end of which a brief history and physical
examination, clinic BP measurements and laboratory tests
were performed, and another echocardiogram was acquired.
Echocardiography. Two-dimensional targeted M-mode
echocardiography was performed with the patient in the partial
left lateral decubitus position. The M-mode cursor was di-
rected through the center of the two-dimensional parasternal
short-axis image at or just distal to the tips of the mitral valve
leaflets, with strip chart recording on paper at 50 mm/s.
Particular care was taken to achieve image planes orthogonal
to the LV anatomic long axis and to optimize definition of
endocardial and epicardial interfaces.
Using the apical four-chamber view, mitral inflow was
sampled by placing the Doppler pulsed wave sample volume in
the LV at the level of the mitral annulus (19), with optimal
adjustment of gain and filtration to achieve the acoustically
purest frequency and narrowest spectral envelope obtainable.
Continuous wave Doppler from the apical window was used to
record the signals of aortic valve closure and mitral valve
opening simultaneously (19).
Abbreviations and Acronyms
BP 5 blood pressure
ECG 5 electrocardiogram
LV 5 left ventricular
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Echocardiograms were interpreted at the echocardiography
central reading laboratory. The average of 3 beats was utilized
for all measurements. To minimize variability, studies were
measured by a single, experienced sonographer reader. Mea-
surement of ventricular septum, LV cavity, posterior wall and
left atrium were performed according to American Society of
Echocardiography criteria (20). The peak velocity (E) of early
diastolic filling was taken at the maximal excursion of the
leading edge of the mitral time–velocity integral, and the late
diastolic peak filling rate (A) was determined from the maxi-
mal excursion of the time–velocity integral with atrial contrac-
tion. The interval was determined between the onset of the
QRS complex on the simultaneously recorded electrocardio-
gram (ECG) and the onset of Doppler mitral flow, as well as
the interval between the QRS onset and Doppler aortic
closure. The isovolumetric relaxation time was determined as
the difference between these intervals. After comparability
with the real-time two-dimensional echocardiographic para-
sternal images on videotape was determined, M-mode paper
strip chart recordings were analyzed utilizing a commercially
available off-line analysis system (Microsonics Datavue II)
coupled to a digitizing tablet with a spatial resolution of 0.001
in. (0.0025 cm).
Using the formula of Devereux et al. (21), LV mass (g) was
calculated as 0.80 3 (1.04 3 [(Septal thickness 1 LV cavity
diameter 1 Posterior wall thickness)3 2 (LV cavity diame-
ter)3] 1 0.6 g and normalized by body surface area determined
by nomogram (22). Meridional end-systolic wall stress, LV
fractional shortening, cardiac output and peripheral resistance
were computed as previously described (23).
Intraobserver errors for septal and posterior wall thick-
nesses and LV diastolic dimension were 8.2%, 6.9% and 2.3%,
respectively. Interobserver errors (comparison with reader
J.S.G.) were 9.1%, 8.7% and 7.9% respectively. For E and A
peak diastolic velocities, the intraobserver errors were 8.7%
and 7.9%, respectively. The Pearson coefficient for intraob-
server correlation of LV mass was 0.82, diastolic dimension
0.80, posterior wall 0.84, septal wall 0.83, E velocity 0.76 and A
velocity 0.86.
Ambulatory BP monitoring. Ambulatory BP monitoring
was performed using commercially available equipment
(SpaceLabs, Advanced Technology Laboratories), and analy-
ses was carried out by a central laboratory. BP was recorded at
30-min intervals and analyzed as the average of 24-h recording,
the average of awake BP (8 AM to 10 PM) and average early
morning hour BP (4 AM to 10 AM).
Clinical measurements. BP, body weight, electrolytes and
an ECG were obtained at every visit. BP was recorded with a
mercury sphygmomanometer in both sitting and standing
positions, according to American Heart Association guidelines
with systolic BP defined as phase I and diastolic BP as phase V
Korotkoff sounds.
Statistical analysis. Results are presented as mean value 6
SD. Comparative data were analyzed by two-way repeated
measures analysis of variance. Between-group comparisons
were made using Bonferroni correction for multiple compari-
sons.
The independent contribution of change of descriptors to
change in LV mass and its components was assessed using
stepwise multivariate regression analysis. The variables en-
tered into the model were change in casual systolic and
diastolic BP, change in 24-h average systolic and diastolic BP,
change in body weight, treatment selection, race, gender and
age.
Analysis of variance, covarying for treatment effect as well
as race, age and gender, was performed for change in BP
variables against change in LV mass. If selection of therapy
had no effect on LV mass independently of the magnitude of
change in BP, the treatment effect would be expected to be
nonsignificant.
All statistical tests were two-sided. Differences resulting in
p values #0.05 were considered significant, except for tests
involving interactions, which were done at a significance level
of 0.10. All variables were evaluated using the actual measure-
ments and the change from baseline.
The statistical computer package SAS, versions 5 and 6, was
used to generate the statistical analyses (24).
Results
Two hundred forty-one patients from 18 centers entered
the study. Of these, 159 were randomized to isradipine and 82
patients to hydrochlorothiazide. A total of 43 patients taking
isradipine (27%) and 28 hydrochlorothiazide (34.1%) with-
drew from the study primarily for uncontrolled hypertension,
patient request or side effects. There were 36 patients (27
taking isradipine, 9 hydrochlorothiazide) who completed the
study but had inadequate echocardiographic data; they were
thus excluded from the efficacy analysis.
A total of 134 patients (89 receiving isradipine, 45 receiving
hydrochlorothiazide) had complete echocardiographic and
clinical data and were considered evaluable. The average dose
of isradipine used after drug titration was 6.8 6 2.5 mg twice





Male 74 (83%) 34 (76%)
Female 15 (17%) 11 (24%)
White 28 (32%) 9 (20%)
Black 61 (68%) 35 (78%)
Other 1 (2%)
Age (yr) 56 6 11 58 6 9
Duration of HTN (yr) 11 6 9 13 6 8
Height (cm) 170 6 7.5 172.5 6 10
Weight (kg) 89.7 6 16 91 6 13.6
Sitting SBP (mm Hg) 158 6 16 161 6 17
Sitting DBP (mm Hg) 101 6 7 101 6 6
Sitting HR (beats/min) 74 6 9 78 6 9
*p 5 NS for all comparisons. Data presented are mean value 6 SD or
number (%) of patients. DBP 5 diastolic blood pressure; HR 5 heart rate;
HTN 5 hypertension; SBP 5 systolic blood pressure.
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daily and that of hydrochlorothiazide was 41 6 12 mg daily.
Tables 1 and 2 present the demographic characteristics and
echocardiographic variables of the evaluable patients at base-
line. There were no differences between the two treatment
groups.
Effects on BP. Table 3 presents BP changes from baseline
at 3 and 6 months of maintenance therapy and at the end of the
2-week placebo washout phase after the completion of active
therapy. Both isradipine and hydrochlorothiazide reduced
sitting systolic BP significantly, but the reduction with hydro-
chlorothiazide was greater at all study intervals. Diastolic BP
was reduced significantly with both treatments and to the same
extent.
On 24-h ambulatory BP monitoring there was significant
reduction of average systolic and diastolic BP at 3 and 6
months of maintenance therapy in both treatment groups.
However, there was a greater reduction in systolic BP with
hydrochlorothiazide at 6 months (Table 3) during awake and
early morning hours.
Effects on LV mass and left atrial size. At 3 months, LV
mass was reduced significantly with both treatments (Fig. 1,
Table 4), but at 6 months, there was reduction of LV mass only
with hydrochlorothiazide. At 2 weeks after treatment, the
change in LV mass with isradipine was not statistically different
from LV mass at baseline, whereas with hydrochlorothiazide
LV mass remained less than that at baseline.
Although an equivalent decrease in wall thickness occurred
with both drugs at 6 months, LV diastolic dimension was
reduced significantly only with hydrochlorothiazide treatment
and returned to baseline at 2 weeks after therapy.
Decrease in left atrial dimension occurred at 3 and 6
months with hydrochlorothiazide but not with isradipine (Ta-
ble 4).
LV function. With isradipine there was a small increase in
fractional shortening at 3 months (20.017 6 0.07, p 5 0.048),
accompanied by decreases in end-systolic stress (27.9 6
18.1 3 103 dynes/cm2 at 3 months; 25.0 6 21 3 103 dynes/cm2
at 6 months, both p # 0.04). Although end-systolic wall stress
also decreased with hydrochlorothiazide (211.8 6 21.0 3
103 dynes/cm2 at 3 months, 212.3 6 19.0 3 103 dynes/cm2 at 6
months, both p # 0.001), there were no significant increases in
fractional shortening, possibly consequent to decreases in LV
volume.
Diastolic LV filling. Decreases in peak late diastolic filling
with isradipine and hydrochlorothiazide were not statistically
significant. Patients receiving hydrochlorothiazide evidenced
decreases in early diastolic peak filling velocity of 5.1 6 11 cm/s
(p 5 0.009) at 3 months and 5.8 6 13 cm/s at 6 months (p 5
0.015). Isovolumetric relaxation time at baseline (94 6 24 ms)
did not differ between treatment groups. There were no
significant changes during or after treatment with either drug
and no significant between group differences.
Descriptors of change in LV mass. Treatment selection
significantly affected the slope relation of BP variables to
change in LV mass at 6 months (analysis of covariance). On
stepwise multivariable regression analysis, treatment selection







Septum (mm) 13.3 6 2.0 12.9 6 2.0
Posterior wall (mm) 12.6 6 1.9 12.3 6 1.7
Left atrium (mm) 43.0 6 6.1 42.1 6 5.4
Aortic dimension (mm) 33.9 6 5.0 33.9 6 3.9
LV diastolic dimension (mm) 51.3 6 5.8 52.2 6 5.6
LV systolic dimension (mm) 32.1 6 6.1 33.0 6 6.2
LV mass (g) 345 6 80 343 6 89
LV mass index (g/m2) 170 6 36 165 6 36
*p 5 NS for all comparisons. LV 5 left ventricular.








D From Baseline Between-Group D*
Sitting SBP (mm Hg)
3 mo 217.4 6 15 ,0.001 226.0 6 14.8 ,0.001 0.003
6 mo 217.6 6 16 ,0.001 225.3 6 16.9 ,0.001 0.006
2 wk post 21.6 6 16 0.291 27.7 6 14.5 ,0.001 0.055
Sitting DBP (mm Hg)
3 mo 212.9 6 8.1 ,0.001 213.2 6 6.4 0.001 0.51
6 mo 212.4 6 8.7 ,0.001 213.1 6 6.9 0.001 0.53
2 wk post 23.8 6 9.6 ,0.001 25.0 6 7.2 0.001 0.62
Ambulatory BP monitoring
Average SBP, 4 AM–10 AM (mm Hg)
3 mo 216 6 13 ,0.001 223 6 14 0.001 ,0.001
6 mo 214 6 15 ,0.001 223 6 11 0.001 ,0.001
Average SBP, 8 AM–10 PM (mm Hg)
3 mo 215 6 12 ,0.001 222 6 11 0.001 ,0.001
6 mo 215 6 13 ,0.001 223 6 11 0.001 ,0.001
*There were no differences between the two groups in diastolic blood pressure during ambulatory monitoring. BP 5 blood pressure; post 5 after completion of
active therapy; D 5 change; other abbreviations as in Table 1.
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(partial r2 5 0.082, p 5 0.001), change in average 24-h systolic
BP (partial r2 5 0.032, p 5 0.029) and change in average casual
systolic BP (partial r2 5 0.017, p 5 0.096) were predictors of
change in LV mass. Gender, race, age and change in body
weight did not enter the model at the 0.10 level of significance.
Separate analysis of the components of LV mass showed a
significant treatment effect of hydrochlorothiazide on LV
diastolic dimension.
Discussion
Despite previous expectations and a study design intended
to maximize the ability to detect the effects of isradipine versus
the “control” arm (hydrochlorothiazide), the results of the
present study showed that reduction of LV mass was in fact
fourfold greater with hydrochlorothiazide than with isradipine.
Moreover, reduction of LV mass at 3 months with isradipine
did not persist at 6 months of therapy. Importantly, the small
decrease in LV mass with isradipine was due to a decrease in
septal and posterior wall thickness, with no change in LV cavity
size, whereas with hydrochlorothiazide the decrease in LV
mass was due to a decrease in both wall thickness and LV
cavity dimension. This finding underscores the importance of
the preload contribution to LV mass and hypertrophy previ-
ously emphasized by Ganau et al. (25).
Analysis of treatment differences in LV mass after adjusting
for weight, BP, race and gender showed that the magnitude of
decrease in systolic BP reduction was a significant predictor of
LV mass reduction with hydrochlorothiazide. However, even
after adjustment for systolic BP, drug selection itself remained
independently predictive of LV mass reduction, suggesting
that factors other than reduction of systolic BP, or the other
covariates that were analyzed, may be associated with the
efficacy of hydrochlorothiazide for LV mass reduction. None-
theless, better reduction of systolic BP with hydrochlorothia-
zide is also of importance given the contribution of systolic BP
to the morbidity of hypertension.
Previous studies. In many studies (13,14), diuretic drugs
have been relatively ineffective for reduction of LV mass.
Moreover, there is a theoretic basis (26,27) for ineffective
regression of LV hypertrophy with diuretic drugs, whereby
diuretic drugs either fail to inhibit neurohormonal mechanisms
of hypertrophy or actually result in their reflex activation (27).
However, our finding of a substantial reduction in LV mass
with a diuretic drug is in agreement with that of the Treatment
of Mild Hypertension Study (TOMHS) of 844 patients. Al-
though patients in all treatment arms showed reduction of LV
mass (28), LV mass decreased more than placebo only in the
chlorthalidone treatment group (29).
The Department of Veterans Affairs trial of monotherapy
in mild to moderate hypertension (31), a trial of six active
drugs (30), also found that the diuretic drug (hydrochlorothi-
azide) was effective for reduction of LV mass, whereas the
calcium blocker (dilitiazem) was not.
Effects on LV function. In theory, loss of contractile pro-
tein with LV mass reduction may place the left ventricle at risk
for sudden increases in afterload. However, in the present
study, as in others (8,15,32), LV systolic chamber function
(fractional shortening) was not diminished in either treatment
group, even after discontinuation of therapy. During treat-
ment, the small increase in fractional shortening with isradi-
pine that accompanied the decrease in end-systolic stress may
Figure 1. Change in LV mass and its components (septal wall thick-
ness, posterior wall thickness, LV cavity dimension) during and after
treatment. HCTZ 5 hydrochlorothizide; ISRAD 5 isradipine. *p #
0.05, **p # 0.001 versus baseline. †p # 0.001 between treatment
groups.
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reflect decreased afterload consequent to vasodilation. Al-
though the failure of fractional shortening to increase with
hydrochlorothiazide despite a decrease in end-systolic stress
could be interpreted as depression of myocardial function, it
also could be due to decreased preload consequent to the
decrease in LV volume.
LV diastolic filling velocity measured by Doppler reflects
complex interactions of loading, heart rate, autonomic tone,
myocardial distensibility, active relaxation and other factors
(33). Hence, it is difficult to offer a meaningful physiologic
explanation for the observed effects of isradipine and hydro-
chlorothiazide on LV filling. However, the greater decrease in
early diastolic peak filling velocity with hydrochlorothiazide
than with isradipine may have been consequent to volume
effects of hydrochlorothiazide.
Limitations of the study. Because the study design speci-
fied a cutoff value for LV mass as an inclusion criterion, there
is the risk that changes in LV mass, particularly the relatively
small decrease with isradipine at 3 months, could be due to a
regression to the mean. However, this is considered unlikely
because two pretreatment echocardiograms were obtained—
one to determine the selection criterion for LV mass and the
second to use as a baseline value. Also, some but not all
echocardiographic measurements used to calculate LV mass
decreased with isradipine. Moreover, regression to the mean
could not account for the large difference in LV mass reduc-
tion between treatment groups.
Additionally, the study dropouts due primarily to inade-
quate BP control (44% with isradipine, 45% with hydrochlo-
rothiazide) may limit the generalizability of the study. How-
ever, the success of the initially assigned drug in achieving and
maintaining diastolic BP is consistent with that found previ-
ously (30). Furthermore, the study design permitted evaluation
of the drug actually used, without confounding of study results
by crossovers to medication not initially assigned or by use of
additional medication.
Clinical implications. Because LV mass incrementally
adds to the cardiovascular risk of hypertension, and reduction
of LV mass may confer benefits above and beyond those
attributed to BP control alone, it seems reasonable to use
drugs that are particularly effective for reduction of LV mass as
well as reduction of BP.
Data from the present study and others suggest that diuretic
drugs are more effective than some other drugs in reducing LV
mass. This, together with the dramatic reductions in stroke and
cardiac events (34,35) associated with diuretic drug use, par-
ticularly in elderly hypertensive patients with a high prevalence
of LV hypertrophy, as well as the lower cost of diuretic drugs,
strengthens recommendations (36) for the use of diuretic drugs
as first-line therapy in hypertension.
Table 4. Change From Baseline in Echocardiographic Measurements
Isradipine (n 5 89)











3 mo 20.4 6 1.0 0.003 20.0 6 0.7 0.866 0.117
6 mo 20.5 6 1.1 ,0.001 20.3 6 0.8 0.05 0.409
2 wk post 20.3 6 1.4 0.226 20.4 6 1.0 0.007 0.515
Posterior wall, diastole (mm)
3 mo 20.3 6 1.1 0.069 20.2 6 1.1 0.166 0.839
6 mo 20.4 6 1.3 0.006 20.4 6 1.1 0.039 0.982
2 wk post 20.3 6 1.3 0.06 20.4 6 0.9 0.009 0.964
Left atrium (mm)
3 mo 0.0 6 3.9 0.987 21.8 6 3.8 0.009 0.039
6 mo 0.9 6 4.4 0.061 21.8 6 3.5 0.006 0.003
2 wk post 0.4 6 4.4 0.71 20.8 6 3.4 0.405 0.516
LV diastolic dimension (mm)
3 mo 0.0 6 3.6 0.993 22.5 6 3.6 ,0.001 ,0.001
6 mo 0.6 6 3.3 0.116 22.8 6 3.3 ,0.001 ,0.001
2 wk post 0.4 6 3.6 0.48 20.6 6 3.1 0.609 0.391
LV mass (g)
3 mo 212.9 6 47.3 0.036 231.6 6 41.8 ,0.001 0.078
6 mo 210.6 6 48.2 0.123 243.4 6 44.7 ,0.001 ,0.001
2 wk post 27.1 6 50.2 0.362 224.0 6 41.0 0.003 0.286
LV mass index (g/m2)
3 mo 26.8 6 24.0 0.033 214.3 6 20.2 ,0.001 0.075
6 mo 25.8 6 24.7 0.12 219.8 6 21.2 ,0.001 ,0.001
2 wk post 24.3 6 25.5 0.224 211.4 6 19.2 0.003 0.35
Abbreviations as in Tables 2 and 3.
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Appendix
Participating Centers and Investigators for the
Isradipine Study Group
University of Tennessee, Memphis, Tennessee: William Applegate, MD;
Bennett Cardiac Center, Charlotte, North Carolina: Tyson Bennett, MD;
Veterans Affairs Medical Center, Memphis, Tennessee: William G. Cushman,
MD; University of Southern California, Los Angeles, California: Vincent
DeQuattro, MD; Georgetown University Hospital, Washington, D.C.: Gilbert
Eisner, MD; Mid Carolina Cardiology, Charlotte, North Carolina: William
Herndon, MD; University of North Carolina, Chapel Hill, North Carolina: Alan
Hinderliter, MD; Mayo Clinic, Jacksonville, Florida: Prince K. Zachariah, MD;
5282 Medical Drive, Suite 614, San Antonio, Texas: P. Michael Kaihlanen, MD;
Ochsner Clinic, New Orleans, Louisiana: Franz Messerli, MD; Veterans Affairs
Medical Center, Washington, D.C.: Vasilios Papademetriou, MD; The Clinical
Research Associates, Nashville, Tennessee: Jon Levine, MD; Westside Medical
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